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Abstract
Background Therapeutic hypothermia (TH) is an established intervention to improve the outcome of neonates with moderate-
to-severe hypoxic-ischemic encephalopathy resulting from perinatal asphyxia. Despite this beneficial effect, TH may further 
affect drug elimination pathways such as the glomerular filtration rate.
Objectives The objective of this study was to quantify the effect of TH in addition to asphyxia on mannitol clearance as a 
surrogate for the glomerular filtration rate.
Methods The effect of asphyxia and TH (mild vs moderate/severe) on mannitol clearance was assessed using a population 
approach, based on mannitol observations collected in the ALBINO (ALlopurinol in addition to TH for hypoxic-ischemic 
Brain Injury on Neurocognitive Outcome) trial, as some were exposed to a second dose of 10 mg/kg intravenous mannitol as 
placebo to ensure blinding. Pharmacokinetic analysis and model development were conducted using NONMEM version 7.4.
Results Based on 77 observations from 17 neonates (TH = 13), a one-compartment model with first-order linear elimina-
tion best described the observed data. To account for prenatal glomerular filtration rate maturation, both birthweight and 
gestational age were implemented as clearance covariates using an earlier published three-quarters power function and a 
sigmoid hyperbolic function. Our final model predicted a mannitol clearance of 0.15 L/h for a typical asphyxia neonate 
(39.5 weeks, birthweight 3.25 kg, no TH), lower than the reported value of 0.33 L/h for a healthy neonate of similar age 
and weight. By introducing TH as a binary covariate on clearance, the additional impact of TH on mannitol clearance was 
quantified (60% decrease).
Conclusions Mannitol clearance was decreased by approximately 60% in neonates undergoing TH, although this is likely 
confounded with asphyxia severity.
Trial Registration ClinicalTrials.gov identifier NCT03162653.
The ALBINO Study Group coordinating investigator names are 
present in Acknowledgements section.
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1 Introduction
Perinatal asphyxia is a clinical condition comprising peri-
natal hypoxia, hypercarbia, and combined metabolic and 
respiratory acidosis [1]. Perinatal asphyxia is a multi-organ 
disease with moderate-to-severe encephalopathy as a pivotal 
finding to initiate therapeutic hypothermia (TH) within 6 
hours after birth in (near)term neonates [2]. This multi-organ 
disease includes renal impairment, with large inter-individ-
ual variability (IIV) in the glomerular filtration rate (GFR), 
in part explained by asphyxia severity [3]. In 36 asphyxi-
ated neonates (mild, moderate, severe), acute kidney injury 
(AKI) was observed in 1/11 (9%) neonates with moderate 
sphyxia and in 12/25 (56%) neonates with severe asphyxia 
[4]. When we focus on cases that underwent TH (commonly 
restricted to moderate-to-severe HIE), AKI was observed in 
35–42% [5–7]. Creatinine in the first days of life reflects to 
a certain extent maternal kidney function, assay-related dif-
ferences still matter, while reference centile values following 
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Key Points 
Therapeutic hypothermia (TH) improves the outcome 
of neonates with moderate-to-severe hypoxic-ischemic 
encephalopathy resulting from perinatal asphyxia, but 
this is associated with a reduced glomerular filtration 
rate. Mannitol clearance reflects the glomerular filtration 
rate.
Mannitol clearance of a typical asphyxiated neonate 
(39.5 weeks, birthweight 3.25 kg, no TH) was estimated 
at 0.15 L/h, lower than the reported mannitol clear-
ance of a healthy neonate (0.33 L/h) of similar age and 
weight.
Mannitol clearance is further decreased by approxi-
mately 60% in neonates who undergo TH, but this 
is likely confounded with asphyxia severity, as TH 
is applied only to newborns with moderate or severe 
asphyxia.
2  Methods
2.1  Setting and Study Design
(Near)term neonates who fulfilled perinatal asphyxia criteria 
and early signs of evolving encephalopathy (cfr infra) and 
were included in the ALBINO trial were administered an ini-
tial dose of study medication (intravenous, either 20 mg/kg 
of allopurinol or mannitol, placebo needed to enable blind-
ing) shortly (i.e. within 45 min) after birth. This is because 
both the verum and the mannitol are provided as a freeze-
dried sodium salt with the same visual aspect. A second dose 
of either allopurinol or mannitol (both 10 mg/kg, intravenous 
over 10 min) was administered 12 h after the first dose in 
neonates who subsequently underwent TH. The primary 
endpoint of this study is death or severe neurodevelopmental 
impairment vs survival without severe neurodevelopmental 
impairment at the age of 2 years [12].
Patients were eligible for the ALBINO trial if they ful-
filled at least one of the perinatal asphyxia criteria: (1) pH 
< 7 or base deficit ≥ 16 mmol/L, (2) need for ongoing car-
diac massage for ≥ 5 min postpartum; (3) need for adrenalin 
administration during resuscitation; and (4) Apgar score ≤ 5 
after 10 min postpartum; in combination with two or more 
early signs of evolving encephalopathy: (1) altered state 
of consciousness; (2) hypotonia or hypertonia; (3) absent/
insufficient spontaneous respiration requiring respiratory 
support for at least 10 min postpartum; and (4) abnormal 
primitive reflexes/abnormal movements (i.e., seizures). 
Further details of the study protocol have been published 
[12]. The most important exclusion criteria were a gesta-
tional age < 36 weeks, an estimated birth weight < 2500 g, 
or severe congenital abnormalities. Neonates who met the 
ALBINO inclusion criteria, but not the criteria to subse-
quently undergo TH within the first 6 h after birth because of 
a quick and spontaneous recovery (mild HIE), only received 
the first dose of either allopurinol or mannitol. Therapeutic 
hypothermia was initiated within 6 h after birth and aimed 
for a core temperature of 33.5 °C for 72 h. Subsequently, 
there was a slow rewarming to normothermia and after 
rewarming, body temperature was stabilized at 36.5 °C for 
24 h in moderate-to-severe HIE cases in accordance with the 
published guidelines [2].
2.2  Pharmacokinetics, Blood Sampling, 
and Analysis
Pharmacokinetics was a predefined secondary outcome 
parameter of the ALBINO trial [12]. This sub-study was 
conducted in four specific centers (Amsterdam, Nürnberg, 
Tübingen, Utrecht) involved in the ALBINO trial. Blood 
sampling was combined with clinically indicated blood 
perinatal asphyxia do not yet exist. Consequently, their clini-
cal use to assess individual renal impairment in early neona-
tal life remains poor [5].
Asphyxia with TH results in a clinically significant, tran-
sient decrease in mean GFR (− 40 to − 50%), with gesta-
tional age (GA) and hypoxic-ischemic encephalopathy (HIE) 
stage as additional covariates [3]. Mannitol, a hexitol, is 
eliminated exclusively by the kidneys where it undergoes 
free filtration through the glomeruli. While there is limited 
tubular reabsorption (10%) in adults, the tubular transporter 
processes in neonates are still immature. Moreover, mannitol 
is not metabolized, thereby fulfilling the criteria for being 
an exogenous substance for GFR measurement [8]. Conse-
quently, mannitol clearance (CL) has been used to describe 
GFR, including maturation and growth from term neonatal 
age onwards [9–11]. The ALBINO (ALlopurinol in addition 
to TH for hypoxic-ischemic Brain Injury on Neurocognitive 
Outcome) trial is a randomized blinded placebo-controlled 
trial with mannitol administration in the placebo group, as 
this enabled visual blinding [12]. As pharmacokinetics was a 
predefined secondary endpoint of this trial, this provided us 
with the possibility to describe mannitol pharmacokinetics 
and its covariates as a GFR indicator and its variability in 
this specific population of neonates. Information on asphyxia 
severity and related covariates on GFR can subsequently be 
used to better predict renal drug CL, to improve pharma-
cotherapy or to explore physiology-based pharmacokinetic 
(PK) performance [1].
Mannitol Clearance During Whole Body Hypothermia in Asphyxiated Newborns
samples. To limit the number of blood samples per indi-
vidual patient, two sample strategies were developed: A vs 
B at random for either neonates treated with TH or those 
who recovered quickly and did not undergo TH (Table 1) 
[13]. Exact timing of samples were documented and used in 
the analysis. Only samples of neonates exposed to mannitol 
(placebo, n = 17) were analyzed and reported in the current 
sub-study.
For the PK analyses, 0.5 mL of blood was collected in 
 MiniCollect® lithium-heparin tubes (Greiner Bio One, 
Alphen aan den Rijn, the Netherlands). Samples were placed 
in melting ice immediately after collection and centrifuged 
with a speed of 1500–2000g for 10 min at 4–8 °C within 
30 min after collection. Plasma was subsequently separated 
with a pipette and stored in a polypropylene crew cap at 
– 80 °C until analysis.
The Ardena Bioanalytical Laboratory determined manni-
tol concentrations in the plasma samples in accordance with 
Good Clinical Practice guidelines. The assay was validated 
according to the European Medicines Agency guidelines 
(International Conference on Harmonisation Good Clinical 
Practice regulations 2012). Following extraction of mannitol 
by protein precipitation and derivatization (2% acetic anhy-
dride), liquid chromatography-mass spectrometry was used 
to determine total mannitol concentrations. The analytical 
range of the assay was 0.2–200 µg/mL, with the lower limit 
of quantificationbeing 0.2 µg/mL. Accuracy and precision 
of all quality control samples met the predefined acceptance 
criteria. The clinical characteristics were extracted from the 
study data registration files for all cases included in the man-
nitol PK study. Care was taken that investigators involved 
in patient recruitment remained blinded for treatment group 
assignment. The obtained concentration–time profiles of 
mannitol are illustrated in Fig. 1 of the Electronic Supple-
mentary Material.
2.3  Ethics
Oral consent was obtained from at least one parent before 
administering the study medication. After the first dose, 
but before the (potential) second dose, full written paren-
tal consent was obtained [12]. In case parents did not sign 
the informed consent, blood samples already collected 
shortly after birth were destroyed. The medical ethics 
committee of the University Medical Centre Utrecht and 
the Central Committee on Human Research approved the 
study including the specific PK sub-study for the Nether-
lands (NL57237.041.16). The German Federal Authority 
(EudraCT 2016-000222-19) as well as the leading ethics 
committee of Tübingen approved the study for Germany.
2.4  PK Model Development
Pharmacokinetic analysis and model development were 
conducted using NONMEM version 7.4. Results were ana-
lyzed using R version 3.5.2 running under RStudio version 
1.2.5042. Model building was performed in three different 
steps: (1) various structural models (i.e., one- and two-com-
partment models) were tested, after which the most appro-
priate model was selected; (2) a statistical sub-model was 
chosen; and (3) covariates were analyzed. The first-order 
conditional estimation with interaction was used throughout 
the model building process.
The minimum objective function value (OFV) was used 
to compare models. A decrease of 3.84 or greater in OFV 
was considered statistically significant at p < 0.05. Good-
ness-of-fit plots (both observed vs individual- and popu-
lation-predicted concentrations, individual plots, and time 
as well as population predictions vs conditional weighted 
residuals) were evaluated as well.
2.5  Covariate Analysis
Covariates were plotted independently against individual 
estimates of IIV (i.e., η values) to screen for potential fac-
tors that affect mannitol pharmacokinetics (data not shown). 
Covariate-parameter relationships that showed a visual trend 
in the graphical assessment (i.e., birthweight [BW], lactate 
dehydrogenase (LDH), alanine aminotransferase (ALT), GA, 
and TH) were introduced into the base model. Therapeutic 
hypothermia was implemented as a binary covariate in the 
dataset and its parameter-covariate relationship was coded 
as follows (Eq. 1):
Table 1  Sample timing and 
intervals
h hours, min minutes
Group Samples
No hypothermia
 A 15–60 min, 1.5–4 h, 8–12 h, 18–24 h, 60–72 h
 B 15–60 min, 1.5–4 h, 8–12 h, 36–48 h, 96–168 h
Hypothermia
 A 15–60 min, 1.5–4 h, trough level t = 12 h, 13–14 h, 18–24 h, 60–72 h
 B 15–60 min, 1.5–4 h, trough level t = 12 h, 13–14 h, 36–48 h, 96–168 h
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where Pp1 and Pp2 represent the population parameter esti-
mates when cov is either equal to 0 or 1, Pi equals the indi-
vidual parameter estimate of the ith subject, and cov is the 
covariate. BW, ALT, and LDH were implemented in the 
model using a power function (Eq. 2):
where Pp and Pi represent the population estimates and 
individual parameter estimates of the ith subject, cov is the 
covariate, and b is the power exponent. The relationship 
between GA and mannitol CL was investigated using a sig-
moid hyperbolic function (Eq. 3) [14]:
where Pp and Pi represent the population estimates and 
individual parameter estimates of the ith subject, cov is the 
covariate, Hill (gamma) is the Hill coefficient, and  TM50 the 
maturation half time.
The significance of the covariates was statistically tested 
using a stepwise covariate method involving testing of 
covariate relationships in a forward inclusion (reduction of 
OFV of 6.63; p < 0.01) and backward exclusion (reduc-
tion of OFV of 10.8; p < 0.001) [15]. Furthermore, some 
covariates (i.e., GA on CL, BW on CL, and TH on CL) were 
included into the final model based on scientific plausibility 
and prior knowledge [16–18].
2.6  Model Evaluation
The final PK model was evaluated using two methods: (1) 
the sampling importance resampling (SIR) method and 
(2) the normalized prediction distribution error (NPDE) 
method. The SIR procedure was used to assess the uncer-
tainty and to calculate the 95% confidence intervals (CIs) of 
the parameter estimates of the final model. The procedure 
was run with 2000 final samples and 1000 resamples. A 
covariance matrix from the successful final model run was 
used as a proposal distribution. Results of the SIR procedure 
were evaluated with the graphical diagnostic methods pro-
vided by the sir package in PsN version 5.0.0. To determine 
the accuracy of the model predictions, a NPDE analysis was 
performed using the NPDE package in R version 3.5.2 [19]. 
Computation of NPDEs has been described previously by 
Brendel et al. [20]. Briefly, prediction discrepancies were 
obtained as the percentile of each observation within its 
predicted distribution. After decorrelation of the obser-
vations and the predictions, prediction distribution errors 
(1)Pi = Pp1 ⋅ (1 − cov) + Pp2 ⋅ cov













were calculated. These were then normalized by inverting 
the cumulative density function, after which NPDEs were 
obtained. A model describes the data well if the calculated 
NPDEs follow a normal distribution with a mean of 0 and 
a variance of 1.
3  Results
3.1  Patients and Clinical Characteristics
The PK analysis was based on a total of 77 observations 
from 17 neonates of whom 13 underwent TH. Table 2 sum-
marizes all patient characteristics.
3.2  PK Model Building
A one-compartment model, which was parameterized in 
terms of CL and V, was preferred over a two-compartment 
model as it described the data more accurately. Indeed, the 
OFV of the one-compartment model (OFV = 450) was 
significantly lower (p < 0.05) as compared with the OFV 
of the two-compartment model (OFV = 454). Moreover, 
the decrease in OFV was accompanied with improved 
goodness-of-fit plots (data not shown). In addition, various 
residual error models (i.e., additive, proportional, and com-
bined) were evaluated. The combined additive and propor-
tional error model best described the residual variability as 
reflected by the lower OFV and improved goodness-of-fit 
plots (data not shown). Table 3 depicts the population PK 
parameters that were derived from the base model.
3.3  Systematic Covariate Analysis
Following visual inspection of the covariate-η plots, the 
covariates GA, BW, ALT, LDH, and TH were selected for 
further evaluation (Fig. 1). However, because of the limited 
Table 2  Clinical characteristics of patients included in the study
IQR interquartile range, absolute difference between Q3 and Q1
Characteristic Median [IQR]
Patients (n) 17
Gestational age (weeks) 39.5 [1] 
Birthweight (kg) 3.4 [0.5]
Height (cm) 54.1 [3] 
Age at start of cooling (h) 2.1 [4.8]
Lactate dehydrogenase (U/L) 1520 [746]
Alanine aminotransferase (U/L) 63.8 [44.8]
Thompson score 9.5 [9] 
Therapeutic hypothermia (n [%]) 13 [76.5]
Inotropes (n [%]) 8 [47.1]
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amount of data available, none of the tested covariates sig-
nificantly affected either CL or V, as determined by the 
stepwise covariate method. We therefore included covari-
ates based on prior knowledge and scientific plausibility. 
More specifically, the allometric relationship between BW 
and PK parameters such as CL and V is well documented. 
Consequently, we decided to implement BW as a covari-
ate on both CL and V using an allometric equation with 
exponents fixed to 0.75 for CL and 1 for V. This resulted in 
a drop in the OFV of 5 points (p < 0.05) and reduced the 
unexplained variability on CL from 1.41 to 1.35 (7%) and 
on V from 0.221 to 0.165 (7.5%).
Rhodin et al. showed that postmenstrual age (PMA) with 
a sigmoid hyperbolic function well described GFR matura-
tion across the entire pediatric population.  TM50, the time 
at which maturation reaches half the adult value, was esti-
mated at 47.7 weeks, whereas the Hill coefficient, which 
describes the slope of the sigmoidal curve, was estimated 
at 3.4 [14]. In our study, PMA (i.e., the sum of GA and 
postnatal age [PNA]) was almost fully determined by GA as 
data were collected until 3 days after birth. Consequently, to 
describe GFR maturation, we introduced GA as a covariate 
in the model using the aforementioned sigmoid hyperbolic 
function, with  TM50 and the Hill coefficient fixed to 47.7 
and 3.4, respectively. Although the OFV did not drop to a 
statistically significant extent, the unexplained variability 
on CL did decrease from 1.41 to 1.27 (16%). Furthermore, 
various studies have previously shown that TH affects renal 
CL in neonates [16, 17]. Based on these observations, we 
decided to include TH as a covariate on CL. This led to a 
considerable decrease in the unexplained variability in CL 
(from 1.41 to 1.22 [22%]), whereas the OFV remained virtu-
ally unchanged.
3.4  Final PK Model and Internal Evaluation
Table 3 summarizes the estimated population PK param-
eters of both the base model and the final model together 
with the values obtained from the SIR analysis. Therapeutic 
hypothermia was found to decrease mannitol CL, and thus 
GFR, by approximately 60% (39% relative standard error) 
compared with the estimated mannitol CL of neonates who 
did not undergo TH. The SIR analysis confirmed the preci-
sion of the parameter estimates that were obtained from the 
final model as the SIR medians were close to the estimates 
and were within the 95% confidence interval. Moreover, the 
observed vs population- and individual-predicted concentra-
tion plots (Fig. 2a and b) as well as the conditional weighted 
Table 3  Estimated parameters of the base model and final pharmacokinetic model
BW birthweight, CL clearance, CV coefficient of variation, GA gestational age, N.D. not determined, Pop population, RSE relative standard error, 
SIR sampling importance resampling procedure (the median birth weight in this cohort was 3.4 kg), V volume of distribution
a CL = PopCL × (BW/median BW)θCL × ((GAHill)/(TM50Hill +  GAHill)) × θTH
b V = PopV × (BW/median BW)θV
c Values were fixed according to [14]
Parameter Units Base model Final pharmacokinetic 
model
SIR final pharmacokinetic model
Mean (% RSE) Mean (% RSE) Median 95% confidence interval
Structural model parameters
 CL L/h 0.0760 (33) 0.441 (10) 0.440 0.320–0.544
 V L 1.440 (12) 1.400 (13) 1.415 1.132–1.705
Covariates
 Asphyxia treated with hypothermia 
(θTH)
0.399 (39)a 0.395 0.194–0.616
 Birthweight on CL (θCL) 0.75  Fixeda N.D. N.D.
 Birthweight on V (θV) 1  Fixedb N.D. N.D.
 Hill coefficient 3.40  Fixeda, c N.D. N.D.
 Maturation half time  (TM50) Weeks 47.7  Fixeda, c N.D. N.D.
Inter-individual variability
 CL CV% 176 (32) 137 (65) 1.093 0.547–2.165
 V CV% 49.7 (19) 41.9 (40) 0.170 0.0846–0.316
Residual variability
 Proportional % 29.2 (22) 29.2 (23) 29.4 24.1–35.5
 Additive µg/mL 0.358 (53) 0.358 (36) 0.359 0.184–0.484
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residuals vs population-predicted concentration and time 
plots (Fig. 2c and d) did not show any considerable trends 
or bias.
In addition, both the mean (0.004) and variance (1.003) 
of the NPDEs did not differ significantly from 0 and 1 (p 
> 0.05), indicating that the model describes the data well. 
However, both the histogram and QQ plot of the NPDEs 
did show a slight deviation from normality (Fig. 2e and f).
4  Discussion
Although TH has demonstrated to have beneficial effects 
on neurological outcomes, reducing a neonate’s body tem-
perature may further affect physiological processes such as 
those involved in drug elimination [21]. The current study 
therefore aimed to quantify the impact of TH in addition to 
asphyxia on mannitol CL, as a surrogate for GFR. Because 
TH was only started in infants with moderate-to-severe HIE 
according to current guidelines, and non-TH infants studied 
herein only had mild HIE, it was only possible to compare 
the combined effect of TH and more severe asphyxia with 
no TH and milder asphyxia.
A PK model was developed based on 77 observations that 
originated from 17 (near)term neonates. A one-compartment 
model with linear first-order elimination described the data 
best as reflected by the low OFV and improved goodness-of-
fit plots (data not shown). Interestingly, none of the investi-
gated covariates significantly affected CL or V, as determined 
by the stepwise covariate method. This may be a problem 
of a small sample size, but as we had no access to addi-
tional data, we decided to introduce covariates in the model 
Fig. 1  a–f Covariate-η plots of the covariates (gestational age, birthweight, alanine aminotransferase, lactate dehydrogenase, and therapeutic 
hypothermia) that showed a clear trend (|corr| > 0.3 or p < 0.05). CL clearance, V volume of distribution
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based on prior knowledge and scientific plausibility rather 
than statistical significance. This is because previous stud-
ies have clearly indicated that both maturation and growth 
are implicated in the increase in neonatal glomerular func-
tion [10, 14, 18]. Maturation is typically described using an 
age-related factor, such as PMA, whereas the most common 
descriptor for growth is BW [22, 23]. There are, however, 
different views on whether age-related covariates should be 
used to describe prenatal GFR maturation. For instance, Rho-
din et al. indicated that GFR maturation before birth is best 
described using both BW and PMA, whereas De Cock et al. 
suggested that implementing BW alone suffices to describe 
antenatal GFR maturation as BW and PMA repeatedly use 
the same information [14, 18]. To account for prenatal GFR 
maturation, we decided to introduce both BW and GA (in this 
dataset de facto similar to PMA) as covariates on CL using 
an allometric three-quarters power function and a sigmoid 
hyperbolic function, respectively [14]. This decision was 
based on the observation that the covariate-η plots of BW 
and GA showed a clear trend (Fig. 1), whereas the correlation 
between BW and GA was rather weak (correlation coefficient 
= 0.34), suggesting that BW alone could only partly explain 
the inter-individual differences in prenatal GFR maturation. 
By simultaneously implementing BW and GA as covariates, 
the IIV on CL decreased considerably more (− 24.8 %) as 
compared with the ‘BW-only’ model (− 10.5%).
Glomerular filtration rate is known to increase rapidly 
in the first few days after birth [24]. This is commonly 
Fig. 2  a Observed vs population-predicted concentrations and b 
observed vs individual-predicted concentrations. The solid blue 
line represents loess smoothing. c Conditional weighted residuals 
(CWRES) vs population-predicted concentrations and d time. The 
solid blue line represents loess smoothing. e Distribution of the nor-
malized prediction distribution errors (NPDEs). The solid red line 
represents a normal distribution, whereas the solid blue line repre-
sents the actual distribution of the NPDEs. f QQ plot of NPDEs
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accounted for in PK models using either PNA and/or PMA 
as covariates on CL [14, 18, 25]. However, several studies 
have suggested that PMA is insufficient to describe post-
natal GFR maturation as it ignores the impact of birth on 
GFR [18, 26]. Indeed, Salem et al. showed that in a group 
of neonates with the same PMA values, neonates with a 
higher PNA have higher GFR values as compared with 
more mature cases at birth, but with a lower PNA [26]. In 
other words, postnatal GFR maturation is best described 
using PNA rather than PMA. Consequently, we intro-
duced PNA as a covariate on CL using both a linear and 
power function. However, the estimated effect of PNA on 
CL was negative in all tested cases, suggesting that GFR 
decreases with increasing PNA (data not shown). As this 
does not make sense from a physiological point of view, we 
decided to exclude PNA as a covariate on CL. We can only 
speculate, but one of the potential explanations might be 
that (although intended different, Table 1) there was some 
skewed sample collection over postnatal life in this cohort 
as all samples collected from 59 h (cf Fig. 2d) onwards 
were collected in cases that underwent HT. In addition, we 
did not implement LDH and ALT as covariates in the final 
model even though their covariate-η plots showed a clear 
trend. This decision was based on the observation that their 
overall trend was almost entirely determined by a single 
(same) outlier (Fig. 1d and e).
Our final model predicted a mannitol CL of 0.15 L/h for 
an asphyxiated neonate with a GA of 39.5 weeks and a BW 
of 3.25 kg who did not undergo TH. This is lower than the 
reported value of 0.33 L/h for a healthy neonate of approxi-
mately the same age and weight [10]. These results are to be 
expected as perinatal asphyxia is known to affect GFR, and 
thus mannitol CL [27].
The effect of hypothermia on renal drug CL in neonates 
with perinatal asphyxia has been investigated previously 
by several groups. For instance, Cristea et al. found that 
amikacin CL in neonates with perinatal asphyxia treated 
with TH was decreased by approximately 40% compared 
with controls (neonates treated for suspected early-onset 
sepsis), while a study conducted by Mark et al. found a 
25.5% decrease in gentamicin CL following TH in 16 cases 
compared with seven cases with similar clinical character-
istics but in whom HT were not provided [17, 28]. These 
findings are further supported by studies conducted in pigs 
that suggested that the intensity of the hypothermic treat-
ment may determine the extent to which renal CL capacity 
decreases [29, 30]. However, these observations are con-
tradicted by Liu et al. who failed to find an effect of TH on 
renal drug CL [31]. Because of these conflicting results, 
we decided to introduce TH as a binary covariate on CL 
as the η vs covariate plots showed a clear trend (Fig. 1f). 
We are hereby aware that TH was only initiated in cases 
with moderate-to-severe HIE. The IIV on CL decreased 
by approximately 20%, justifying our decision to include 
TH as a covariate. Our model predicted that mannitol CL, 
a surrogate for GFR, decreased by approximately 60% 
on average in neonates who underwent TH (Table 3). 
Moreover, we observed a large IIV (137%) in estimated 
mannitol CL. This is not unexpected as asphyxia severity 
is known to be correlated with kidney damage and our 
dataset contained neonates with perinatal asphyxia from 
mild (no TH) to moderate to severe as not all cases under-
went TH, be it overweighted in TH cases (13/17) [4, 27]. 
This may also explain why we observed such a profound 
effect of TH on GFR. More specifically, we were unable 
to disentangle the effect of perinatal asphyxia from the 
effect of hypothermia on mannitol CL. The effect that we 
observed was therefore likely confounded with the sever-
ity of asphyxia. In an attempt to disentangle the impact 
of perinatal asphyxia from the impact of TH on manni-
tol CL, we explored whether introducing age at the start 
of cooling as a covariate would allow us to quantify CL 
before and after the initiation of TH. However, as only one 
measurement on average was available before the start of 
TH, mannitol CL before the initiation of TH could not be 
estimated.
An additional relevant limitation of our model is its lim-
ited applicability. More specifically, because of the conflict-
ing reports in the literature regarding the effect of TH on 
GFR and the fact that TH as an independent covariate did 
not affect mannitol CL to a statistically significant extent in 
our model, we suggest that the results in the current study 
should not be extrapolated to other renally cleared drugs. 
However, our results do provide additional evidence that 
perinatal asphyxia affects GFR compared to healthy con-
trols. Consequently, care should be taken when dosing this 
patient population with renally cleared drugs, be it that we 
are unable to provide any guidance in relevant covariates 
within this population. In addition, future studies should be 
conducted that pool data on GFR estimates from different 
centers to further investigate the effect of TH on GFR.
5  Conclusions
We developed a model that accurately described the phar-
macokinetics of mannitol, a surrogate for GFR, in neonates 
with perinatal asphyxia. Gestational age and BW were 
implemented as covariates to account for prenatal GFR 
maturation, whereas TH was introduced as a binary covari-
ate on CL to quantify the impact of hypothermia on mannitol 
CL. Therapeutic hypothermia was found to decrease man-
nitol CL by approximately 60%, although this effect is likely 
confounded with asphyxia severity.
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